This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Apellis price target lowered to $18 from $20 at Wedbush
Wedbush lowered the firm’s price target on Apellis (APLS) to $18 from $20 and keeps a Neutral rating on the shares. Overall, the Q4 report from Apellis was largely as anticipated with the company preannouncing key results in January, the firm notes. Management anticipates flat Syfovre pricing into FY26 and more limited growth.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
Disclaimer & DisclosureReport an Issue
- Apellis price target lowered to $18 from $20 at Wedbush
- Apellis price target lowered to $44 from $45 at Citi
- Balanced Outlook on Apellis: Near-Term Revenue Uncertainty and Developing Long-Term Upside Justify Hold Rating
- Apellis price target raised to $48 from $45 at H.C. Wainwright
- Apellis Pharmaceuticals: Buy Rating Supported by Blockbuster Empaveli Potential, Sustainable Syfovre Growth, and Expanding Kidney Franchise
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
